Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aurora

- PMLiVE

JCVI announces advice for autumn COVID-19 booster vaccine eligibility

The Committee has advised offering the booster to those at high risk of serious disease

- PMLiVE

MHRA authorises HIPRA Human Health’s COVID-19 vaccine for use in UK

Bimervax is the ninth COVID-19 vaccine to be authorised by the UK medicines regulator

- PMLiVE

US NIH launches mid-stage long COVID trials to evaluate at least four treatments

One trial will test a longer dosing regimen of Pfizer’s antiviral COVID-19 drug Paxlovid

- PMLiVE

Gilead’s COVID-19 treatment approved by FDA for patients with severe renal impairment

Use of Veklury among this patient population has previously been limited

- PMLiVE

Novavax’s COVID-19 vaccine granted full marketing authorisation in EU

The EC’s decision was supported by positive results from a phase 3 trial evaluating Nuvaxovid

- PMLiVE

FDA advisory committee backs updated COVID-19 vaccines targeting XBB variants

The XBB.1.5 variant accounted for nearly 40% of all US COVID-19 cases as of early June

- PMLiVE

COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP

Pfizer’s oral antiviral was granted accelerated approval in the US in December 2021

- PMLiVE

Novavax announces positive phase 2 results for COVID-19/influenza vaccine candidates

A combination COVID-19/influenza vaccine is included in the mid-stage study

- PMLiVE

WHO declares end to COVID-19 global public health emergency

The agency’s emergency committee said it is time to transition to long-term management of the pandemic

- PMLiVE

WHO announces launch of new pandemic preparedness initiative

The guidance focuses on respiratory pathogens, including influenza and RSV

- PMLiVE

WHO and global partners launch new effort to address falling childhood vaccination rates

Over 25 million children missed at least one vaccination in 2021 alone

- PMLiVE

NHS spring COVID-19 booster programme opens up for those at highest risk

Around five million people are eligible for the booster in line with the JCVI’s advice

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links